[Features of care of patients with cardiovascular diseases and cognitive disorders].

Abstract

Due to the increase in life expectancy of the population, the proportion of people with cognitive impairment (CI) is also increasing. Today, it is known that cardiovascular diseases (CVD) are a significant risk factor for the development of CI. At the same time, the main substrate of CVD, including cerebrovascular events, is atherosclerosis. Statins are one of the most studied classes of drugs in the prevention of CVD. Atorvastatin (Liprimar) is one of the most studied and most frequently prescribed statins that has proven its effectiveness and safety in patients with a wide range of cardiovascular pathology. CI, in turn, lead to a decrease in functional autonomy, ability to work and adherence to treatment, thereby closing the vicious circle. Thus, therapy for CI should be initiated as early as possible, since they are a progressive disorder that eventually transforms into dementia. One of the drugs that has been used for 50 years for symptomatic therapy of CI, including dementia, chronic cerebrovascular and organic brain damage, is nicergoline (Sermion).